Merck KGaA starts Phase III Parkinson's trial

Merck KGaA has launched a late-stage study of safinamide for Parkinson's disease. The drug is designed to help improve motor function, but the study will also explore its affect on cognitive function and quality of life. Some 650 volunteers are being signed up to get two doses of the drug in combination with dopamine agonists in comparison to dopamine agonists alone. Merck gained a worldwide license to the therapy from Newron last year.

- see this release
- here's the AFX report on the trial

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.